This facility was created to provide EBRI researchers with one of the most powerful tools in today´s research: the use of transgenic mice. The sequence of mouse genome has been determined and mice are currently used to model various diseases. In the transgenic mouse facility, animals are genetically engineered for either the elimination of a specific gene or insertion of a modified gene.

The production of genetically modified mice gives researchers the instrument to study the function of a specific gene at every level, from molecular to behavioral. In addition, creation of transgenic mice is crucial for the study of diseases, such as Alzheimer´s and Parkinson´s diseases, as it provides animal models that can be studied to better understand the pathophysiology of any illness and explore the possibility of new therapeutic approaches.

Group Components

Cecilia Tiveron ( Passed away, 17 December 2010) (EBRI) Coordinator Scientist  c.tiveron@ebri.it 

Federico la Regina (EBRI) Research Technician  f.laregina@ebri.it

Publications

Capsoni S, Tiveron C, Vignone D, Amato G, Cattaneo A. Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration. Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12299-304. Epub 2010 Jun 21.

Capsoni S, Tiveron C, Amato G, Vignone D, Cattaneo A. Peripheral neutralization of nerve growth factor induces immunosympathectomy and central neurodegeneration in transgenic mice. J Alzheimers Dis. 2010;20(2):527-46.

Nucera C, Muzzi P, Tiveron C, Farsetti A, La Regina F, Foglio B, Shih SC, Moretti F, Della Pietra L, Mancini F, Sacchi A, Trimarchi F, Vercelli A, Pontecorvi A. Maternal thyroid hormones are transcriptionally active during embryo-foetal development: results from a novel transgenic mouse model. J Cell Mol Med. 2010 Oct;14(10):2417-35.

Tiranti V, Viscomi C, Hildebrandt T, Di Meo I, Mineri R, Tiveron C, D Levitt M, Prelle A, Fagiolari G, Rimoldi M, Zeviani M Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat. Med. 2009 Jan 11.

Terao M, Kurosaki M, Barzago MM, Fratelli M, Bagnati R, Bastone A, Giudice C, Scanziani E, Mancuso A, Tiveron C, Garattini E. Role of the molybdoflavoenzyme aldehyde oxidase homolog 2 in the biosynthesis of retinoic acid: generation and characterization of a knockout mouse. Mol Cell Biol. 2009, 29, 357-77.

De Luca G, Russo MT, Degan P, Tiveron C, Zijno A, Meccia E, Ventura I, Mattei E, Nakabeppu Y, Crescenzi M, Pepponi R, Pèzzola A, Popoli P, Bignami M.  A role for oxidized DNA precursors in Huntington´s disease-like striatal neurodegeneration. PLoS Genet. 2008,  4(11).

Ciana P, Biserni A, Tatangelo L, Tiveron C, Sciarroni AF, Ottobrini L, Maggi A  A novel peroxisome proliferator-activated receptor responsive element-luciferase reporter mouse reveals gender specificity of peroxisome proliferator-activated receptor activity in liver. Mol Endocrinol. 2007, 21, 388-400.

Dell’Agnello C, Leo S, Agostino A, Szabadkai G, Tiveron C, Zulian A, Prelle A, Roubertoux P, Rizzuto R, Zeviani M Increased longevity and refractoriness to Ca(2+)-dependent neurodegeneration in Surf1 knockout mice. Hum Mol Genet. 2007, 16, 431-44.

Divet A, Paesante S, Grasso C, Cavagna D, Tiveron C, Paolini C, Protasi F, Huchet-Cadiuo C, Treves S, Zorzato F Increased Ca(2+) storage capacity of the skeletal muscle sarcoplasmic reticulum of transgenic mice over-expressing membrane bound calcium binding protein junctate. J Cell Physiol. 2007, 213, 464-74.

Rucci F, Cattaneo L, Marrella V, Sacco MG, Sobacchi C, Lucchini F, Nicola S, Della Bella S, Villa ML Imberti L, Gentili F, Montagna C, Tiveron C, Tatangelo L, Facchetti F, Vezzoni P, Villa A  Tissue-specific sensitivity to AID expression in transgenic mouse models. Gene  2006, 377,150-8.

Forlino A, B Gualeni, F Pecora, S Della Torre, R Piazza, C Tiveron, L Tatangelo, A Superti-Furga, G Cetta and A Rossi  Insights from a transgenic mouse model on the role of SLC26A2 in health and disease, Novartis Foundation, 2006,  273:193-206; discussion 206-12, 261-4.